Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Atreca, Inc. BCEL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
38/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.00
+4344.4%

Atreca, Inc. (BCEL) is a Biotechnology company in the Healthcare sector, currently trading at $0.09. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 3 out of 7 criteria passed.

Analyst consensus target is BCEL = $4 (+4344.4% upside).

Financials: revenue is $770,000, -27.7%/yr average growth. Net income is $91M (loss), growing at -12.5%/yr. Net profit margin is -11756.5% (negative). Gross margin is -819.6% (-913.9 pp trend).

Balance sheet: total debt is $64M against $78M equity (Debt-to-Equity (D/E) ratio 0.81, moderate). Current ratio is 4.79 (strong liquidity). Debt-to-assets is 41.2%. Total assets: $155M.

Analyst outlook: 4 / 8 analysts rate BCEL as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 0/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$4.00
▲ 4344.44% Upside
Average Price Target
The 12-month price target for Atreca, Inc. is $4.00.

BCEL SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BCEL

✓
VALUE Pass
100/100
BCEL trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $4, implying +4344.4% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
BCEL: -27.7%/yr revenue is, -12.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet BCEL: Debt-to-Equity (D/E) ratio 0.81 (moderate), Current ratio is 4.79 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
64/100
Analyst outlook: 4 / 8 analysts rate BCEL as buy (50%). Analyst consensus target is $4 (+4344.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
BCEL: Net profit margin is -11756.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.052-1.2
Volume122.12K
Avg Volume (30D)267K
Market Cap$3.57M
Beta (1Y)1.03
Share Statistics
EPS (TTM)-2.35
Shares Outstanding$38.59M
IPO Date2019-06-20
Employees90
CEOJohn A. Orwin
Financial Highlights & Ratios
Revenue (TTM)$770K
Gross Profit$-6.31M
EBITDA$-90.44M
Net Income$-90.53M
Operating Income$-103.79M
Total Cash$70.5M
Total Debt$63.88M
Net Debt$33.06M
Total Assets$155.03M
Price / Earnings (P/E)-0
Price / Sales (P/S)4.63
Analyst Forecast
1Y Price Target$4.00
Target High$4.00
Target Low$4.00
Upside+4,344.4%
Rating ConsensusBuy
Analysts Covering8
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS04965G1094

Price Chart

Track all markets on TradingView
BCEL
Atreca, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.05 52WK RANGE 1.20

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 HARP
HARP
Harpoon Therapeutics, Inc.
$23.01
+0.09%
 ALEC
ALEC
Alector, Inc.
$2.41
+3.43%
 BDTX
BDTX
Black Diamond Therapeutics, Inc.
$2.66
-2.21%
 TCRR
TCRR
TCR2 Therapeutics Inc.
$1.48
+0.00%
 PASG
PASG
Passage Bio, Inc.
$10.86
+0.46%
 FIXX
FIXX
Homology Medicines, Inc.
$0.93
+0.77%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message